

BASICS OF PHARMACOVIGILANCE 2023

Training agenda:

1.DAY

09:00 – 10:30

- **Pharmacovigilance basics, introduction**
 - Brief introduction to Pharmacovigilance – history, existence, objectives, outcomes
 - Description of basic PhV activities, experience with adverse reaction reporting
- **Adverse reactions**
 - Definitions, reporting sources
 - Evaluation
 - Valid/invalid cases
 - Special situations
 - Literature as a source of adverse effects
 - Examples from practice

10:30 – 11:00 – break

11:00 – 12:30

- **Organisation of Pharmacovigilance**
 - PhV organisation at European / national level
 - Organisations at company level (GVP, EMA, PSMF, SOP)
 - Global PhV vs. local PhV
 - Pharmacovigilance training
 - Monitoring of legislation
- **Pharmacovigilance from a global and local perspective**
 - Description of activities of the local person
 - Description of activities of the global person
 - Differences between countries (legislative requirements)
 - Links and differences in activities
 - Relevant training

12:30 – 13:30 – lunch break

13:30 – 15:00

- **Relationship between Pharmacovigilance and Registration**
 - Pre-registration phase and registration phase, post-registration phase
 - Registration dossier – RMP, CO, NCO, ACO, ANCO, Similarity Assessment
 - When does Pharmacovigilance start?
 - Setting up proper communication between departments
 - What should not be forgotten?

- **Control mechanisms in PhV (Quality Management)**
 - SOP, PSMF
 - Key Performance Indicators (KPIs)
 - Risk based approach
 - Training and audit plans
 - Business continuity
 - Corrective and preventive actions management (CAPA)
 - Archiving

15:00 – 15:30

- **Discussions and questions**
-

2.DAY

09:00 – 10:30

- **Specific PhV Documentation**
 - Detailed description of individual pharmacovigilance documents – RMP
 - More detailed description of individual pharmacovigilance documents – PSUR
 - Brief description of CO, NCO, ACO, ANCO etc.

- **Pharmacovigilance database**
 - Working with PhV databases – reporting of AEs (examples, specific cases, quality)
 - xEVMPD (Art. 57)
 - EVDAS
 - SPOR
 - Local company databases

10:30 – 11:00 – break

11:00 - 12:30

- **Benefit/Risk assessment, signals**
 - B/R evaluation process
 - Methods for determining B/R
 - Signal
 - Distinction between company and EU responsibilities

- **Pharmacovigilance outputs**
 - PhV directed to authority, own society and the public

12:30 - 13:30 - lunch break

13:30 - 15:00

- **Audit/inspection experience**
 - External/internal
 - How to behave during inspection/audit
 - Rights, GDPR, administrative law
 - Examples and experience from inspections and audits over the last two years

15:00 - 15:30

- **Discussions and questions**